Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs)
$50.85
pos +0.00
+0.00%
Today's Range: 50.04 - 50.97 | TEVA Avg Daily Volume: 7,234,300
Last Update: 04/17/14 - 4:04 PM EDT
Volume: 0
YTD Performance: 26.87%
Open: $0.00
Previous Close: $49.91
52 Week Range: $36.26 - $54.70
Oustanding Shares: 946,868,125
Market Cap: 48,148,244,156
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 5 5 5
Moderate Buy 0 0 0 0
Hold 11 12 10 10
Moderate Sell 0 0 0 0
Strong Sell 1 1 3 3
Mean Rec. 2.30 2.56 2.74 2.74
Latest Dividend: 0.29
Latest Dividend Yield: 2.23%
Dividend Ex-Date: 02/20/14
Price Earnings Ratio: 33.50
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
33.50 34.10 29.08
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.86% 32.46% 1.68%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.00 0.26 0.08
Net Income -34.40 -0.62 -0.28
EPS -33.60 -0.60 -0.26
Earnings for TEVA:
EBITDA 5.60B
Revenue 20.31B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $1.23 $1.20 $4.76 $4.72
Number of Analysts 11 10 13 12
High Estimate $1.44 $1.41 $5.63 $5.50
Low Estimate $1.12 $1.14 $4.40 $4.10
Prior Year $1.12 $1.20 $5.01 $4.76
Growth Rate (Year over Year) 9.42% 0.00% -4.91% -0.82%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Ed Ponsi

 | Apr 15, 2014 | 12:00 PM EDT

 Stocks with good fundamentals are getting some respect.

By

Bret Jensen

 | Apr 8, 2014 | 9:00 AM EDT

A pullback of at least 10%, seems like a distinct possibility.

bullishTeva added to US Focus List at Citi

Mar 28, 2014 | 8:15 AM EDT

TEVA was placed on the US Focus List, Citigroup said. $60 price target. Company offers the bst risk/reward of the group.

bullishTeva upgraded at Goldman

Mar 19, 2014 | 8:25 AM EDT

TEVA was upgraded from Sell to Neutral, Goldman Sachs said. Copaxone slowdown is largely priced in and the underlying business can deliver growth. $52 price target. 

bullishTeva upgraded at JP Morgan

Mar 14, 2014 | 7:21 AM EDT

TEVA was upgraded to Neutral, JP Morgan said. $49 price target. Company has several potential paths to creating shareholder value. 

bullishTeva upgraded at Leerink

Mar 6, 2014 | 7:59 AM EST

TEVA was upgraded to Outperform, Leerink Swann said. $65 price target. Cash flow should stabilize and M&A activity in likely to accelerate in the industry. 

By

Bret Jensen

 | Jan 10, 2014 | 1:00 PM EST

These three carry nice valuations.

By

Paul Price

 | Jan 7, 2014 | 11:00 AM EST

The pharma company looks suitable for a buy-write combination trade.

bearishTeva Pharmaceuticals downgraded at JP Morgan

Nov 4, 2013 | 8:28 AM EST

TEVA was downgraded to Underweight from Neutral, JP Morgan said. $38 price target. Too much uncertainty following CEO departure.

By

Bret Jensen

 | Oct 18, 2013 | 12:00 PM EDT

Some European names look ripe for investment right now.

The new Fed Chief said this at a recent meeting of the Economic Club of NY ... "We have in...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.